Global Sepsis Diagnostics Market 2017-2021
About Sepsis Diagnostics
Sepsis is a three-staged syndrome; it starts with systemic infections leading to severe sepsis and ultimately causing sepsis shock, which is regarded as a medical emergency. Population with weak immune system, which include children, older adults, and people with chronic diseases such as cancer, AIDS, diabetes, are prone to sepsis.
Sepsis occurs mainly due to bacterial, viral, and fungal infections. Gram-negative bacilli such as E. coli, P. aeruginosa, E. corrodens, and Haemophilus influenzae (which occurs mainly in neonates) are the main agents that cause infection, leading to sepsis. Other bacteria which causes sepsis are S. aureus, Streptococcus species, Enterococcus species, and Neisseria species.
Technavio’s analysts forecast the global sepsis diagnostics market to grow at a CAGR of 6.74% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global sepsis diagnostics market for 2017-2021. To calculate the market size, the report considers the sales, volume and value of global sepsis diagnostics segment.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Sepsis Diagnostics Market 2017-2021
Technavio recognizes the following companies as the key players in the global sepsis diagnostics market: bioMérieux and T2 Biosystems
Other Prominent Vendors in the market are: Alere, Abionic, AdvanDx, Aethlon Medical, AusDiagnostics, Beckman Coulter, Beckton Dickinson, Momentum Bioscience, Bio-Rad Laboratories, Bruker, Cepheid, Curetis, CytoSorbents, Fast Track Diagnostics, F. Hoffmann-La Roche, Fujirebio Europe, Hansa Medical, Hain Lifescience, Immunexpress, Inflammatix, Merck, miacom diagnostics, Mitsubishi Chemical Europe, Nanōmix, QIAGEN, Radiometer, Response Biomedical, Sepset Biosciences, Siemens Healthineers, TCS Biosciences, and Thermo Fisher Scientific.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increasing use of biomarkers for sepsis. The increased preference for biomarkers offers homogeneity of risk or disease status of the patient within limited time and provides precision diagnosis will increase its adoption rate. Biomarkers are used as diagnostic tools for the diagnosis of a disease or abnormal conditions of sepsis, including severe sepsis. The accuracy and timely detection of sepsis are regarded as the significant challenges. Therefore, the health providers rely on nonspecific clinical and laboratory signs.”
According to the report, one of the major drivers for this market is Rising prevalence of hospital acquired infection (HAIs) globally. Increasing cases of HAIs in the population is the leading cause of sepsis. HAI is also known as the nosocomial infection, which may affect the population during hospitalization or after the patient is discharged from the hospital. The presence of immunocompromised patients in hospitals, transmission of the pathogen between the staff and the patient, and the presence of microorganisms and contaminated particles in the hospital environment are the major factors that result in HAIs. The number of cases for HAIs is on the rise across the world, leading to septicemia. This drives the demand for sepsis diagnostics worldwide.
Further, the report states that one of the major factors hindering the growth of this market is High cost of sepsis treatment. The high cost of sepsis treatment is regarded as one of the market constraints, which affects the growth of the sepsis diagnostics market. Therefore, the high price of procedures decreases the adoption rate of this product, especially in the reference laboratories and small clinics where the budget allocated is very less. However, the cost-efficient treatment is likely to increase the adoption rate during the forecast period.
bioMérieux, T2 Biosystems, Alere, Abionic, AdvanDx, Aethlon Medical, AusDiagnostics, Beckman Coulter, Beckton Dickinson, Momentum Bioscience, Bio-Rad Laboratories, Bruker, Cepheid, Curetis, CytoSorbents, Fast Track Diagnostics, F. Hoffmann-La Roche, Fujirebio Europe, Hansa Medical, Hain Lifescience, Immunexpress, Inflammatix, Merck, miacom diagnostics, Mitsubishi Chemical Europe, Nanōmix, QIAGEN, Radiometer, Response Biomedical, Sepset Biosciences, Siemens Healthineers, TCS Biosciences, and Thermo Fisher Scientific.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook